Collaboration with Dr. John Robbins **NIH-USA**



One of the Largest cGMP manufacturers in the world


1.5 Billion doses of vaccines sold

TYPBAR

Vi Capsular Polysaccharide Typhoid Vaccine







Distributed by:



Genome Valley, Hyderabad - 500 078, A.P. India. www.hharathiotech.com

Typhoid Infection - Prevention is more Crucial than Treatment

Antibiotic resistant strains of S. typhi are increasing rapidly, including multidrug resistant strains and those less sensitive to quinolones, such as ciprofloxacin. We are running out of treatment options, making vaccination against typhoid even more imperative*





Vi Capsular Polysaccharide Typhoid Vaccine

Typhoid fever continues to be a serious public health problem in many developing countries*

According to the World Health Organization (WHO), there are 16 million to 33 million cases & 500,000 to 600,000 deaths from typhoid fever annually.**


"Global mortality estimates for typhoid fever (216,000 - 600,000 or more) place typhoid in the range of several priority infectious diseases"
FONDATION MERIEUX - Annecy, France, Les Pensières, April 2-4, 2007

** Ref: Initiative for Vaccine Research. Typhoid fever. (Accessed August 23, 2007,

Efficacy and Safety of TYPBAR

Double - Blind & Randomized Clinical Study confirms:

- Proven Safety & Immunogenicity
- Demonstrated Efficacy
- Proven track record with usage in more than 50 countries



- No Animal Derived Growth Media, no BSE/TSE contaminants
- Least Reactogenic due to low endotoxin levels
- Also available as a Pre-Filled Syringe (ready to use injection)